Skip to main content
. 2023 Aug 25;29(9):2216–2223. doi: 10.1038/s41591-023-02494-2

Extended Data Table 4.

Pharmacodynamic measurements of lipid parameters: percent change from baseline at day 85 and MMRM analysis of change from baseline compared to placebo for Apo CIII, total cholesterol and Apo AI for HP SADs of 35 mg, 100 mg, 200 mg or 300 mg of ARO-ANG3

graphic file with name 41591_2023_2494_Tab4_ESM.jpg